Clinical Trial Detail

NCT ID NCT01534260
Title Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hamid Sayar
Indications

acute myeloid leukemia

Therapies

Bortezomib + Sorafenib + Vorinostat

Age Groups: adult

No variant requirements are available.